(HealthDay)—Ropinirole, bromocriptine, and piribedil are associated with the highest incidence rates of adverse effects in Parkinson’s disease, according to a review published online Sept. 4 in CNS Neuroscience & Therapeutics. Bao-Dong Li, from the Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine in China, and colleagues conducted a systematic review to compare the adverse effects of 11 drugs...
Category: <span>Pharmaceutical Updates</span>
Post
Drug combination may improve impact of immunotherapy in head and neck cancer
The combination therapy with TLR agonist and anti-PD-1 agent activates CD8+ T cells (red) in the tumors. Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers may have found...
Post
Researchers identify new target, develop new drug for cancer therapies
A model of Penn’s new approach using DQ611 to target PPT1, which inhibits both mTOR and autophagy. Opening up a new pathway to fight cancer, researchers at the University of Pennsylvania have found a way to target an enzyme that is crucial to tumor growth while also blocking the mechanism that has made past...
Post
A quick jab could reduce stroke damage
A Perth treatment could significantly reduce the damage done to brain cells following a stroke. Diego Milani from the University of Notre Dame Australia has been testing a new compound that has been shown to reduce damage in the brain after a stroke. The compound is made up of 18 molecules of the amino acid arginine...
Post
Nanoparticles from tattoos can travel to the lymph nodes
Scientists have gained a new insight into the behavior of nanoscale particles in tattoo recipients Scientists were already aware that pigments from tattoo ink can travel to the lymph nodes, critical components of the immune system that help fight off viruses and bacteria. Cutting edge X-ray technologies have now provided a look at what much smaller, and more...
Post
There’s a $100 Million Plan to Make a Synthetic Spinal Cord to End Paralysis
IN BRIEF Hugh Herr and his colleagues at MIT’s Center for Extreme Bionics want to change what it means to be disabled. As part of a $100 million, five-year project, the researchers are working on advanced prosthetics that work like real limbs, a synthetic nervous system, and more. A BOLD MISSION Some say experience is the...
Post
Accidental discovery reveals bacteria reduces the effectiveness of chemotherapy drug
Bacteria could be inhibiting the efficacy of traditional cancer treatments Many great scientific discoveries have arisen out of laboratory accidents, from the mistake that led to penicillin, to revelations of LSD’s psychedelic properties after Albert Hoffman unexpectedly absorbed a dose through his fingertips in 1943. The latest serendipitous discovery comes from a cross-contamination accident that...
Post
Targeted antibiotic use may help cure chronic myeloid leukaemia
The antibiotic tigecycline, when used in combination with current treatment, may hold the key to eradicating chronic myeloid leukaemia (CML) cells, according to new research. The University of Glasgow led study, published today in Nature Medicine, demonstrates the effectiveness of combining tigecycline with the drug imatinib – a tyrosine kinase inhibitor (TKI) and standard first-line treatment of patients...
Post
FDA OKs Glaxo’s inhaler, first one to combine three medicines
This photo provided by GlaxoSmithKline PLC shows the company’s Trelegy Ellipta inhaler. Late Monday, Sept. 18, 2017, the Food and Drug Administration approved the product, which is the first inhaler that combines three medicines to ease …more The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients...
Post
Antioxidant supplement cost saving and effective for degenerative eye disease
A supplement that combines antioxidants with zinc and copper is a relatively inexpensive and effective means of halting the progression of a certain type of degenerative eye disease, concludes research published online in the British Journal of Ophthalmology. Given the costs and side effects of the current range of drugs used to treat the ‘wet’ form...